Study of the Biological Activity of Novel Synthetic Compounds with Antiviral Properties against Human Rhinoviruses
Abstract
:1. Introduction
2. Results and Discussion
2.1. Anti-rhinovirus activity
2.2. Time-addiction effect of some novel compounds on HRV14
3. Experimental
3.1. Compounds
- I-6002, (ethyl 4-(2-(biphenyl-4-yl)ethylamino)benzoate),
- I-6230 (ethyl 4-(4-(pyridazin-3yl)phenethylamino)benzoate),
- I-6232 (ethyl 4-(4-(6-methylpyridazin-3yl)phenethylamino)benzoate),
- I-6273 (ethyl 4-(4-(methylisoxazol-5-yl)phenethylamino)benzoate),
- I-6373 (ethyl 4-(4-(3-methylisoxazol-5-yl)phenethylthio)benzoate),
- I-6473 (ethyl 4-(4-(3-methylisoxazol-5-yl)phenethoxy)benzoate),
- I-6501 (ethyl 4-(5-(3-methylisoxazol-5-ylamino)pentylthio)benzoate),
- I-6502 (ethyl 4-(5-(3-methylisoxazol-5-ylamino)pentyloxy)benzoate),
- I-6602 (ethyl 4-(3-(2-(3-methylisoxazol-5-yl)ethoxy)propoxy)benzoate),
- I-6702 (ethyl 4-(3-(1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)propoxy)benzoate).
3.2. Cells and viruses
3.3. Cytotoxic activity
3.4. Inhibition of viral multiplication
3.5. Time-reduction studies of virus yield
4. Conclusions
Acknowledgments
References
- Makela, M.J.; Puhakka, T.; Ruuskanen, O. Viruses and bacteria in the etiology of the common cold. J. Clin. Microbiol. 1998, 36, 539–542. [Google Scholar] [PubMed]
- Melnick, J.L. Portraits of viruses: The picornaviruses. Intervirology 1983, 20, 61–100. [Google Scholar] [CrossRef] [PubMed]
- Melnick, J.L. Properties and classification of hepatitis A virus. Vaccine 1992, 10 (Suppl. 1), S24–S26. [Google Scholar] [CrossRef]
- Rueckert, R.R. Picornaviruses and their replication. In Fields Virology, 2nd ed.; Channock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B., Eds.; Raven Press: New York, NY, USA, 1990; pp. 507–548. [Google Scholar]
- Wang, L.; Smith, D.L. Capsid structure and dynamics of a human rhinovirus probed by hydrogen exchange mass spectrometry. Protein Sci. 2005, 14, 1661–1672. [Google Scholar] [CrossRef] [PubMed]
- Hadfield, A.T.; Oliveire, M.A.; Kim, K.H.; Minor, I.; Kremer, M.J.; Heinz, B.A.; Shepard, D.; Pevear, D.C.; Rueckert, R.R.; Rossmann, M. Structural studies on human rhinovirus 14 drug-resistant compensation mutants. J. Mol. Biol. 1995, 253, 61–73. [Google Scholar] [CrossRef] [PubMed]
- Ke, Y.Y.; Lin, T.H. Modeling the ligand-receptor interaction for a series of inhibitors of the capsid protein of Enterovirus 71 using several three-dimensional quantitative structure-activity relationship techniques. J. Med. Chem. 2006, 49, 4517–4525. [Google Scholar] [CrossRef] [PubMed]
- Muckelbauer, J.K.; Kremer, M.; Minor, I.; Diana, G.; Dutko, F.J.; Groarke, J.; Pevear, D.C.; Rossmann, M.G. The structure of coxsackie B3 at 3.5 A resolution. Structure 1995, 3, 653–667. [Google Scholar] [CrossRef]
- Barnard, D.L. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 2006, 12, 1379–1390. [Google Scholar] [CrossRef] [PubMed]
- Shih, S.R.; Chen, S.J.; Hakimelahi, G.H.; Liu, H.J.; Tseng, C.T.; Shia, K.S. Selective Human Enterovirus and Rhinovirus Inhibitors: An Overview of Capsid-Binding and Protease-Inhibiting Molecules. Med. Res. Rev. 2004, 4, 449–474. [Google Scholar] [CrossRef] [PubMed]
- Steindl, T.M.; Crump, C.E.; Frederick, G.H.; Langer, T. Pharmacophore modeling, docking, and principal component analysis based clustering: Combined computer-assisted approaches to identify new inhibitors of the human Rhinovirus coat protein. J. Med. Chem. 2005, 48, 6250–6260. [Google Scholar] [CrossRef] [PubMed]
- Verma, R.P.; Hansch, C. Understanding human rhinovirus infections in terms of QSAR. Virology 2007, 359, 152–161. [Google Scholar] [CrossRef] [PubMed]
- Desmond, R.A.; Accortt, N.A.; Talley, L.; Vilano, S.A.; Soong, S.J.; Whitley, R.J. Enteroviral meningitis: Natural history and outcome of pleconaril therapy. Antimicrob. Agents Chemother. 2006, 50, 2409–2414. [Google Scholar] [CrossRef] [PubMed]
- Abraham, G.; Colonno, R.J. Many rhinovirus serotypes share the same cellular receptor. J. Virol. 1984, 51, 340–345. [Google Scholar] [PubMed]
- Holland, J. Enterovirus entrance into specific host cells and subsequent alterations of cell protein and nucleic acid synthesis. Bacteriol. Rev. 1964, 28, 3–13. [Google Scholar]
- Lonberg-Holm, K.; Korant, B.D. Early interaction of rhinoviruses with host cells. J. Virol. 1972, 9, 29–40. [Google Scholar] [PubMed]
- Pevear, D.C.; Tull, T.M.; Seipel, M.E.; Groarke, G.M. Activity of pleconaril against Enteroviruses. Antimicrob. Agents Chemother. 1999, 43, 2109–2115. [Google Scholar] [PubMed]
- Hayden, F.G.; Andries, K.; Janssen, P.A. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 1992, 36, 727–732. [Google Scholar] [CrossRef] [PubMed]
- Zhao, R.; Pevear, D.C.; Kremer, M.J.; Giranda, V.L.; Kofron, J.A.; Kuhn, R.J.; Rossmann, M.G. Human rhinovirus 3 and 3.0 A resolution. Structure 1996, 4, 1205–1220. [Google Scholar] [CrossRef]
- Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P.A.J. In vitro activity of pirodavir (R77975), a substituted-phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 1992, 36, 100–107. [Google Scholar] [CrossRef] [PubMed]
- Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Meth. 1986, 89, 271–277. [Google Scholar]
- Garozzo, A.; Pinizzotto, M.R.; Guerrera, F.; Tempera, G.; Castro, A.; Geremia, E. Antipoliovirus activity of isothiazole derivatives: Mode of action of 5,5′-diphenyl-3,3′-diisothiazole disulfide (DID). Arch. Virol. 1994, 135, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Cutrì, C.C.; Garozzo, A.; Siracusa, M.A.; Sarvà, M.C.; Tempera, G.; Geremia, E.; Pinizzotto, M.R.; Guerriera, F. Synthesis and antiviral activity of a new series of 4-isothiazolecarbonitriles. Bioorg. Med. Chem. 1998, 6, 2271–2280. [Google Scholar] [CrossRef]
Sample Availability: Contact the corresponding author. |
Compounds | Cytotoxic activity | Anti-Rhinovirus activity | Anti-Poliovirus Activity | ||||
---|---|---|---|---|---|---|---|
aCD50 μg/mL | HRV14 bID 50 μg/mL | cPI | HRV39 ID50 μg/mL | PI | ID50 μg/mL | PI | |
I-6002 | 1.5 | 1.5 | 1 | 1.5 | 1 | >1.5 | <1 |
I-6230 | 6.0 | 6 | 1 | 3.1 | 2 | 0.5 | 12 |
I-6232 | 50.0 | 12.5 | 4 | 3.1 | 16 | 0.7 | 71 |
I-6273 | 50.0 | 3.1 | 16 | 1.5 | 32 | 1.4 | 35 |
I-6373 | 12.5 | 1.5 | 8 | 0.37 | 33 | 1.4 | 9 |
I-6473 | 6 | 1.5 | 4 | 0.75 | 8 | 1.4 | 4 |
I-6501 | 6 | 1.5 | 4 | 0.15 | 40 | 2.0 | 3 |
I-6502 | 12.5 | 0.15 | 83 | 0.07 | 17 | 2.6 | 4.8 |
I-6602 | 50 | 0.07 | 714 | 0.07 | 714 | 1.9 | 26 |
I-6702 | 50 | 0.07 | 714 | 0.35 | 142 | 9.1 | 5.5 |
PIRODAVIR | 3.1 | 0.012 | 250 | 0.006 | 500 | 0.1 | 31 |
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Laconi, S.; Madeddu, M.A.; Pompei, R. Study of the Biological Activity of Novel Synthetic Compounds with Antiviral Properties against Human Rhinoviruses. Molecules 2011, 16, 3479-3487. https://doi.org/10.3390/molecules16053479
Laconi S, Madeddu MA, Pompei R. Study of the Biological Activity of Novel Synthetic Compounds with Antiviral Properties against Human Rhinoviruses. Molecules. 2011; 16(5):3479-3487. https://doi.org/10.3390/molecules16053479
Chicago/Turabian StyleLaconi, Samuela, Maria A. Madeddu, and Raffaello Pompei. 2011. "Study of the Biological Activity of Novel Synthetic Compounds with Antiviral Properties against Human Rhinoviruses" Molecules 16, no. 5: 3479-3487. https://doi.org/10.3390/molecules16053479